Key result
In patients with hypertensive nephrosclerosis, use of an ACEI or ARB was associated with significantly fewer infiltrating macrophages in glomeruli compared to no ACEI/ARB use (1.14 vs 2.14 cells/glomerulus, p<0.05).
Why the study?
Does treatment with an ACEI or ARB reduce glomerular macrophage infiltration and MCP-1 expression in patients with hypertensive nephrosclerosis?
Cross-Sectional (n=31)
No
Does treatment with an ACEI or ARB reduce glomerular macrophage infiltration and MCP-1 expression in patients with hypertensive nephrosclerosis?
Blockade of the renin-angiotensin system with ACE inhibitors or ARBs is associated with reduced glomerular macrophage infiltration and MCP-1 expression in human hypertensive nephrosclerosis, suggesting an anti-inflammatory mechanism of renoprotection.
Supports anti-inflammatory effects of ACEI/ARB; hypothesis-generating and requires prospective validation before practice change.
The mechanisms of hypertensive nephrosclerosis are not fully understood. In experimental models of the disease, inflammatory reactions such as macrophage infiltration play an important role. In human hypertensive nephrosclerosis, however, there have been few studies examining the role of inflammation histologically. We investigated whether the number of infiltrating macrophages was increased in human hypertensive nephrosclerosis, and evaluated the effects of a blockade of the renin-angiotensin system on clinical and histological findings. We examined macrophage infiltration using immunohistochemistry in renal biopsy specimens obtained from 16 patients with hypertensive nephrosclerosis, 5 patients with IgA nephropathy, 5 patients with membranous nephropathy, and 5 patients with minimal change nephrotic syndrome. The number of infiltrating macrophages in glomeruli was significantly larger in the patients with hypertensive nephrosclerosis than in those with minimal change nephrotic syndrome. The patients with hypertensive nephrosclerosis were divided into groups based on their use of antihypertensive agents at the time of renal biopsy. We investigated the effects of antihypertensive agents on clinical findings, macrophage infiltration, and monocyte chemoattractant protein-1 expression. There was no difference in clinical findings between the hypertensive groups. The numbers of infiltrating macrophages and monocyte chemoattractant protein-1-positive cells in glomeruli were significantly smaller in patients treated with an angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker, whereas calcium channel blockers had no influence on histological findings. In conclusion, inflammation is involved in the progression of human hypertensive nephrosclerosis and the inflammatory process is inhibited by blocking the renin-angiotensin system.
No takes yet. Share an insight, caveat, or question.
Imakiire et al. (2007) conducted a cross-sectional in Hypertensive nephrosclerosis (n=31). Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II type 1 receptor blocker (ARB) vs. No ACEI/ARB use was evaluated on Number of CD68-positive cells (macrophages) in glomeruli (p=<0.05). In patients with hypertensive nephrosclerosis, use of an ACEI or ARB was associated with significantly fewer infiltrating macrophages in glomeruli compared to no ACEI/ARB use (1.14 vs 2.14 cells/glomerulus, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: